{"url_path":"/sec/sabsw/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1833214/0001193125-26-218195-index.html","accession_number":"0001193125-26-218195","cik":"0001833214","ticker":"SABS","issuer_name":"SAB Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1833214/0001193125-26-218195-index.html","primary_entity_key":"0001833214","primary_entity_name":"SAB Biotherapeutics, Inc."},"word_count":62,"has_tables":true,"body_markdown":"## Item 5. Other Information.\n\nRule 10b5-1 Trading Plans\n\nDuring the three months ended March 31, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act.).\n\n38"}